Semax.

What is being claimed

Semax is often described online as a nootropic or neuroprotective peptide. Those labels compress different questions: molecular effects, symptoms in a defined population, and whether a particular product is authorised and quality-controlled. Keep the product, country and indication attached to every claim.

For the everyday focus and stress questions, compare Semax and Selank and the different outcomes their studies measured.1

Human evidence is not a single package

Some published reports and regional use claims concern specific formulations and clinical contexts. They do not automatically establish effectiveness for cognition in healthy people, mood or exercise-related outcomes, or for a different route of administration. Small or uncontrolled studies also cannot identify uncommon or delayed harms reliably.2

What does a brain-scan study show?

A 2018 study used functional MRI to examine brain networks at rest in 24 healthy volunteers: 14 received intranasal Semax and 10 placebo. Scans were taken before and shortly after administration, and the authors reported a difference in a brain-network measure. An imaging change is not the same as better memory, attention or everyday performance. This small, short experiment did not establish those benefits or long-term safety, and its result cannot be transferred automatically to an online product. For a closer explanation of this and the later Semax–Selank scan report, see what brain imaging can and cannot show.3

What about stroke and other proposed uses?

The English abstract of a 1997 Russian-language report describes 30 people receiving Semax during acute ischemic stroke and a comparison group of 80 receiving conventional treatment. The full report was not reviewed here, and the abstract does not explain allocation or blinding in enough detail to assess the claimed benefit. In its July 2026 compounding review, FDA concluded that the evidence it reviewed was insufficient to support the proposed use for cerebral ischemia. Neither this report nor a brain scan establishes that an online Semax product improves stroke recovery. FDA listed this Russian-language report but did not include it in its effectiveness evaluation because a verified English translation was unavailable. For the later rehabilitation report and emergency context, see Semax and stroke recovery.45

The same FDA review found insufficient evidence to support Semax for migraine or trigeminal neuralgia, a condition involving severe facial pain. The small study it examined had no control group and was not blinded, so it could not establish that Semax caused the reported changes.5

Product and regulator questions

FDA lists Semax among substances for which proposed compounded drugs may pose immunogenicity and peptide-impurity risks and says safety information is absent or limited for proposed routes. A Belgian laboratory identified Semax and Selank in two seized, unlabelled preparations; the researchers noted that the peptides are also sold online, but did not establish where those samples were purchased. Identification of an ingredient does not establish purity, sterility or clinical benefit.12

What a useful study would show

A credible answer would require a defined formulation, manufacturing controls, a prespecified population and outcome, a meaningful comparator, transparent adverse-event reporting and follow-up long enough for the proposed benefit and harms. Mechanistic language cannot substitute for that evidence.1

U.S. compounding policy: a narrow interim position

In October 2026 HHS published a draft interim enforcement-discretion policy covering specified forms of BPC-157, TB-500, KPV, epitalon, MOTS-c and Semax in section 503A compounding. Its Appendix B identifies the chemical form and routes addressed for each peptide; the policy also describes conditions including a patient-specific prescription, ingredient characterization and a single active ingredient. It is a statement of enforcement intent, not FDA approval or proof of safety or effectiveness; it does not establish the legality or quality of an online vial or a multi-ingredient stack. Read the peptide overview and the linked HHS policy for the specific conditions. Checked 5 November 2026. For the conditions and the separate 2027 advisory discussion, see the US policy guide.6